ChimeraX, virtual reality software developed at the UCSF Resource for Biocomputing, Visualization and Informatics, is now the tool of choice for computational structural biologists in the School of Pharmacy. The Jacobson Lab recently used ChimeraX to find a promising new cure for a drug-resistant case of pediatric leukemia.
Dear UCSF School of Pharmacy Family and Friends:
At the UCSF School of Pharmacy we don’t just embrace change, we create it. We have a rich history as drivers of change in our profession, in science, and in education. That passion for change, coupled with a scientific mindset, is clearly evident today in the School, as you’ll read in this Update.
I have much to share, so I’ll get right to it.
With warm regards,
On May 3, in front of a crowd of more than one thousand gathered at Louise M. Davies Symphony Hall in San Francisco, the 122 members of the UCSF School of Pharmacy graduating class of 2019 received their doctor of pharmacy (PharmD) degrees.
“Out of more than 1,100 applicants, we chose each of you—122 bright lights who would clearly bring something unique to the School and the profession,” Dean B. Joseph Guglielmo, PharmD, said. “You have excelled in every way.”
Michael Keiser, PhD, and Kangway Chuang, PhD, want to use machine learning to speed the pace of drug discovery. By digging into the work of another lab, the pair realized how machine learning could lead scientists astray—and came up with methods to avoid its worst pitfalls.
“Challenging the status quo leads to very good things,” said Glen L. Stimmel, PharmD ’72, who has spent a career doing just that. As a motto, it has served him, and his profession, quite well.
Stimmel, the 2019 UCSF Pharmacy Alumni Association Distinguished Alumnus of the Year, has taken his own course through life, and in the process, he helped create the subspecialty of psychiatric pharmacy and expanded the scope of practice for California pharmacists.
The 2019 Mary Anne Koda-Kimble Seed Award for Innovation will fund nine bold research projects, ranging from studies of the molecular underpinnings of cancer to focus groups designed to prepare PharmD students for experiential learning.
Scientists in the UCSF School of Pharmacy recently identified the first drug-binding target site on a molecule known to play a role in Parkinson's disease, opening the door to a new generation of therapies for the condition.
Among all U.S. pharmacy schools, the UCSF School of Pharmacy earned the most research funding from the National Institutes of Health in 2018, totaling nearly $29 million dollars that will support studies spanning the basic to the clinical sciences.